Strongyloidiasis screening: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
|||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 15: | Line 15: | ||
*Refugees and immigrants from endemic areas | *Refugees and immigrants from endemic areas | ||
*[[Immunocompromised|Immunocompromised patients]], especially on [[Corticosteroid medications|corticosteroid therapy]], are the most vulnerable population at risk for developing disseminated disease. | *[[Immunocompromised|Immunocompromised patients]], especially on [[Corticosteroid medications|corticosteroid therapy]], are the most vulnerable population at risk for developing disseminated disease. | ||
*Efforts to diagnose and screen individuals who harbor [[Strongyloides stercoralis|''S.stercoralis'']] should be made for patients who are candidates for [[immunosuppressive]] ( | *Efforts to diagnose and screen individuals who harbor [[Strongyloides stercoralis|''S.stercoralis'']] should be made for patients who are candidates for [[immunosuppressive]] (e.g., [[corticosteroid]]) therapy with relevant geographic history and peripheral [[eosinophilia]]. | ||
==Screening modalities== | ==Screening modalities== | ||
| Line 27: | Line 27: | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Emergency mdicine]] | |||
[[Category:Disease]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Infectious disease]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Dermatology]] | |||
[[Category:Neurology]] | |||
[[Category:Pulmonology]] | |||
Latest revision as of 00:20, 30 July 2020
|
Strongyloidiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Strongyloidiasis screening On the Web |
|
American Roentgen Ray Society Images of Strongyloidiasis screening |
|
Risk calculators and risk factors for Strongyloidiasis screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]
Overview
Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections. Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk. Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.
Screening
- Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections.[1][2][3]
- Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk.[4]
- Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.
Population at risk
- In the U.S., residents of the Southeast may be at risk for strongyloidiasis by growing up in an endemic area.
- Travelers and armed forces personnel may acquire infection during overseas trips to endemic areas (e.g., southeast Asia, Central and South America, and Africa).
- Refugees and immigrants from endemic areas
- Immunocompromised patients, especially on corticosteroid therapy, are the most vulnerable population at risk for developing disseminated disease.
- Efforts to diagnose and screen individuals who harbor S.stercoralis should be made for patients who are candidates for immunosuppressive (e.g., corticosteroid) therapy with relevant geographic history and peripheral eosinophilia.
Screening modalities
Microscopic evaluation
- At least three ova and parasite examinations should be performed on separate days.
Serology
- An enzyme-linked immunosorbent assay (ELISA) for detecting serum IgG (Strongyloides antibody) against a crude extract of the filariform larvae of S.stercoralis is available and should be used as a screening test for strongyloides infection.
- However, because of cross-reactivity with other antigens, definitive diagnosis must also include identification of ova and parasites in stool specimens.
References
- ↑ Mejia R, Nutman TB (2012). "Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis". Curr. Opin. Infect. Dis. 25 (4): 458–63. PMC 3430846. PMID 22691685.
- ↑ Al Maslamani MA, Al Soub HA, Al Khal AL, Al Bozom IA, Abu Khattab MJ, Chacko KC (2009). "Strongyloides stercoralis hyperinfection after corticosteroid therapy: a report of two cases". Ann Saudi Med. 29 (5): 397–401. PMC 2860402. PMID 19700900.
- ↑ "CDC - Strongyloides".
- ↑ "Department of Health | Prevention of opportunistic infections in immunosuppressed patients in the tropical Top End of the Northern Territory of Australia".